Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 52

recruiting
3 987
countries
28
conditions
2 109

761 trials match your criteria

Malignant melanoma+4

Not recruiting

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Autogene Cevumeran

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Study on TTX-030, Budigalimab, and Chemotherapy for Untreated Metastatic Pancreatic Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab

Adenocarcinoma gastric+1

Not recruiting

Study of MK-2870 for Patients with Advanced or Metastatic Stomach Cancer, Comparing Its Effects to a Drug Combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate

Myelofibrosis+1

Not recruiting

Study on the Safety and Effects of Navitoclax and Ruxolitinib for Patients with Myelofibrosis and Myeloproliferative Neoplasms

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Celecoxib

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of AZD7789 for Patients with Advanced or Metastatic Solid Tumors, Including Non-small Cell Lung Cancer and Gastric Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sabestomig

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin

Study Comparing Zanubrutinib with Bendamustine and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Study on S65487 and Azacitidine for Adults with Untreated Acute Myeloid Leukemia Not Suitable for Intensive Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Study on the Safety and Effectiveness of Mosunetuzumab and Atezolizumab for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.